Advanced Biomed Inc. - Common Stock (ADVB)
Healthcare › Services-Medical Laboratories
Price History
Feb 9, 2026 — May 24, 2026Investment Snapshot
- Trading 82% below Graham Number ($22.33) — significant margin of safety
- Piotroski F-Score 4/9 — moderate financial health
- ROE of 49.9% — good return on equity
Advanced Biomed Inc. - Common Stock (ADVB) is a Healthcare company operating in Services-Medical Laboratories, listed on the NASDAQ , with a market capitalisation of $5 million . Key value metrics: P/E ratio 1.2, P/B ratio 0.59, Piotroski F-Score 4 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 2 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Advanced Biomed Inc. - Common Stock — Fundamental Analysis Summary
Advanced Biomed Inc. - Common Stock (ADVB) is trading 82% below its Graham Number of $22.33 — a significant margin of safety by Benjamin Graham's standard. The stock carries a low trailing P/E ratio of 1.2x.
On financial health, ADVB shows a moderate Piotroski F-Score of 4/9, and strong return on equity of 49.9% (sector average: -20.6%), and minimal leverage with a debt-to-equity ratio of 0.14.
StockPik's composite Value Score for ADVB is 90/100 — placing it in undervalued territory. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
ADVB shows earnings declining at 17%.